-$0.37 Earnings Per Share Expected for Pulmonx Co. (NASDAQ:LUNG) This Quarter

Wall Street brokerages forecast that Pulmonx Co. (NASDAQ:LUNGGet Rating) will announce earnings of ($0.37) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Pulmonx’s earnings, with the lowest EPS estimate coming in at ($0.45) and the highest estimate coming in at ($0.22). Pulmonx posted earnings per share of ($0.34) in the same quarter last year, which indicates a negative year-over-year growth rate of 8.8%. The business is expected to issue its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Pulmonx will report full year earnings of ($1.54) per share for the current year, with EPS estimates ranging from ($1.65) to ($1.24). For the next financial year, analysts expect that the company will report earnings of ($1.23) per share, with EPS estimates ranging from ($1.34) to ($1.10). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Pulmonx.

Pulmonx (NASDAQ:LUNGGet Rating) last issued its quarterly earnings data on Wednesday, February 23rd. The company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35). The business had revenue of $13.71 million for the quarter, compared to analysts’ expectations of $14.24 million. Pulmonx had a negative return on equity of 23.15% and a negative net margin of 98.33%. The firm’s quarterly revenue was up 39.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) EPS.

Several analysts have weighed in on LUNG shares. Wells Fargo & Company lowered their price target on Pulmonx from $55.00 to $27.00 and set an “equal weight” rating on the stock in a report on Thursday, February 24th. Canaccord Genuity Group lowered their price target on Pulmonx from $53.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, February 28th. Morgan Stanley lowered their price target on Pulmonx from $37.00 to $30.00 and set an “equal weight” rating on the stock in a report on Friday, February 25th. Bank of America started coverage on Pulmonx in a report on Wednesday, March 2nd. They issued a “neutral” rating and a $28.00 price target on the stock. Finally, Zacks Investment Research raised Pulmonx from a “sell” rating to a “hold” rating in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $36.71.

In related news, CEO Glendon E. French III sold 1,132 shares of the firm’s stock in a transaction that occurred on Tuesday, March 1st. The stock was sold at an average price of $25.91, for a total transaction of $29,330.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Glendon E. French III sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 17th. The stock was sold at an average price of $27.22, for a total value of $340,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 14,090 shares of company stock worth $381,447 over the last quarter. Corporate insiders own 12.56% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LUNG. Morgan Stanley lifted its holdings in Pulmonx by 46.1% in the 2nd quarter. Morgan Stanley now owns 65,036 shares of the company’s stock worth $2,870,000 after buying an additional 20,533 shares during the period. Royal Bank of Canada lifted its holdings in Pulmonx by 113.1% in the 2nd quarter. Royal Bank of Canada now owns 1,839 shares of the company’s stock worth $81,000 after buying an additional 976 shares during the period. SG Americas Securities LLC purchased a new stake in Pulmonx in the 3rd quarter worth approximately $346,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Pulmonx in the 3rd quarter worth approximately $556,000. Finally, Deutsche Bank AG lifted its holdings in Pulmonx by 43.6% in the 3rd quarter. Deutsche Bank AG now owns 35,593 shares of the company’s stock worth $1,280,000 after buying an additional 10,809 shares during the period. Institutional investors and hedge funds own 90.30% of the company’s stock.

LUNG traded down $1.06 during trading on Friday, reaching $24.10. 539,502 shares of the company were exchanged, compared to its average volume of 401,933. The company’s 50-day moving average is $24.94 and its two-hundred day moving average is $30.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.92 and a current ratio of 11.85. Pulmonx has a 12-month low of $18.49 and a 12-month high of $48.77.

Pulmonx Company Profile (Get Rating)

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Recommended Stories

Get a free copy of the Zacks research report on Pulmonx (LUNG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pulmonx (NASDAQ:LUNG)

Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.